Metformin: An Old Drug for the Treatment of Diabetes But a New Drug for the Protection of the Endothelium
Open accessAbstract
OBJECTIVE: To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes. DESIGN: Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg. SETTING: 20 hospital based clinics in England, Scotland, and Northern Ireland. SUBJECTS: 1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years. MAIN OUTCOME MEASURES: Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related to diabetes, and all cause mortality. Surrogate measures of microvascular disease included urinary albumin excretion and retinal photography. RESULTS: Mean blood pressure during follow up was significantly reduced in the group assigned tight blood pressure control (144/82 mm Hg) compared with the group assigned to less tight control (154/87 mm Hg) (P<0.0001). Reductions in risk in the group assigned to tight control compared with that assigned to less tight control were 24% in diabetes related end points (95% confidence interval 8% to 38%) (P=0.0046), 32% in deaths related to diabetes (6% to 51%) (P=0.019), 44% in strokes (11% to 65%) (P=0.013), and 37% in microvascular end points (11% to 56%) (P=0.0092), predominantly owing to a reduced risk of retinal photocoagulation. There was a non-significant reduction in all cause mortality. After nine years of follow up the group assigned to tight blood pressure control also had a 34% reduction in risk in the proportion of patients with deterioration of retinopathy by two steps (99% confidence interval 11% to 50%) (P=0.0004) and a 47% reduced risk (7% to 70%) (P=0.004) of deterioration in visual acuity by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart. After nine years of follow up 29% of patients in the group assigned to tight control required three or more treatments to lower blood pressure to achieve target blood pressures. CONCLUSION: Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
When prescribed in the usual oral dosage range of 250 to ~2550 mg/day for T2DM and in the absence of reduced renal function, peak plasma levels of metformin are unlikely to exceed 15-20 μM, with trough levels between 1-5 μM, and a plasma half-life of approximately 3 to 5 hours.
“When prescribed in the usual oral dosage range of 250 to ~2550 mg/day for the treatment of T2DM and in the absence of reduced renal function, it is unlikely that peak plasma levels of metformin would exceed 15-20 μM, with trough levels of between 1-5 μM, and a plasma half-life of approximately 3 to 5 hours.”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [156]
With a plasma half-life of approximately 3 to 5 hours and subject to dosing schedule, it is unlikely that other than in gut enterocytes a significant cellular accumulation of metformin occurs when used for T2DM.
“However, with a plasma half-life of approximately 3 to 5 hours, and subject to the schedule of dosing, it is unlikely, that other than in gut enterocytes, a significant cellular accumulation of metformin occurs when the drug is used for the treatment of T2DM (34, 155, 156, 159, 160).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [156]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 178 · Cited by 1,515
- Authors
- Kinaan, M., Ding, H., & Triggle, C. R.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Triggle, Chris R.
- Venue
- Medical Principles and Practice
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 24
- Issue
- 5
- Pages
- 401-415
- ISSN
- 1011-7571 (ISSN-L)
- 1423-0151
- PMC
- PMC28659
- OpenAlex
- W1545732697
- Cited by
- 1,515
- References
- 178
- Citations by year
- 2026: 2 · 2025: 19 · 2024: 56 · 2023: 90 · 2022: 101 · 2021: 68 · 2020: 62 · 2019: 75 · 2018: 95 · 2017: 107 · 2016: 111 · 2015: 111 · 2014: 50 · 2013: 28 · 2012: 29
- FWCI
- 24.39
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Medical Principles and Practice (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- tight blood pressure control, type 2 diabetes, hypertension, microvascular complications, macrovascular complications, retinopathy, diabetic nephropathy, albuminuria, stroke, captopril, atenolol, ACE inhibitors, beta-blockers, endothelial protection, metformin, all-cause mortality, cardiovascular risk reduction, retinal photocoagulation, retinopathy progression
- MeSH terms
- Adenylyl Cyclases, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Endothelium, Gluconeogenesis, Humans, Metformin, Mitochondria, Neoplasms, Protein Kinase C, Retrospective Studies, Vascular Diseases, Signal Transduction, Glycation End Products, Advanced, Sirtuins, Glucose Transporter Type 4, AMP-Activated Protein Kinases, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review